Cyplasin Biomedical is a product-oriented, specialty pharmaceutical company focused on developing products for the multi-billion dollar hepatitis C virus (HCV) market. The Company is pleased to announce it has secured US$10M in financing under an equity line of credit (ELOC) with Tangiers Investors, LP to fund the Company's operations and product development programs.